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Objective: Metastatic breast cancer (MBC) is an incurable disease; the treatment of this 
disease prolongs survival, improving the quality of life (QoL) with a balance between efficacy 
and toxicity of the treatment. In recent years, treatment with nab-paclitaxel has improved the 
already known antitumor activity of conventional paclitaxel, in terms of increased efficacy 
and better tolerability. The aim of this study was to evaluate nab-paclitaxel in Italian patients 
with MBC.
Methods: We conducted a retrospective analysis of 90 patients with histologically con-
firmed diagnosis of MBC. To evaluate the efficacy of nab-paclitaxel, overall survival (OS), 
progression-free survival (PFS), and overall response rate were the primary endpoints, 
whereas carbohydrate antigen 15.3 (Ca15.3) reduction, QoL, and tolerability were second-
ary endpoints.
Results: The median OS was 10.4 months, the median PFS was 6.8 months. A considerable 
difference Ca15.3 before and after treatment was observed. Descriptive and regression analyses 
were done to examine the associations between Ca15.3 response and OS, demonstrating good 
correlation, revealing that Ca15.3 reduction is an important predictor of OS.
Conclusion: Nab-paclitaxel is an effective and well-tolerated treatment of patients affected by 
MBC. The drug showed an improved tolerability profile. With all the limitations of the obser-
vational nature of our results, nab-paclitaxel has proven to be an effective and safe therapeutic 
option in patients with MBC.
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Introduction
Breast cancer is the most common cancer in women. In Italy, breast cancer repre-
sents 29% of all female cancers, with ~50,000 new cases a year. Furthermore, about 
10% of new breast cancer cases are diagnosed in the metastatic phase.1,2 Metastatic 
breast cancer (MBC), despite the availability of several active endocrine, cytotoxic 
and targeted agents, remains an incurable disease.3,4 The patients with advanced 
breast cancer frequently receive multiple sequential lines of treatment with pallia-
tive therapeutic targets which consist mainly of controlling symptoms, prolonging 
survival, and improving quality of life (QoL).5 In particular, the taxanes (paclitaxel 
and docetaxel) as single agents and in combination are most frequently used in the 
treatment of early-stage MBC.6,7 The taxanes stabilize microtubules, leading to cell 
cycle arrest and ultimately cell death. Despite the clinical activity against most cancers, 
the taxanes are often associated with alopecia, peripheral neuropathy, neutropenia, and 
serious adverse events of hypersensitivity due to the presence of synthetic solvents 
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in their composition with negative impact on therapeutic 
efficacy.8,9 Nab-paclitaxel (nanoparticle albumin-bound-
paclitaxel; Abraxane®) is a new paclitaxel developed to 
avoid hypersensitivity reactions and toxicities associated 
with solvent-based transport agents, with a more selective 
and more effective therapeutic activity on tumor cells.10,11 
It consists of nanoparticles of paclitaxel reversibly linked 
to human serum albumin of which it uses the natural trans-
port properties. In fact, since the hyper tumor cells produce 
SPARC (secreted protein acidic and rich in cysteine), to 
recall albumin for nutritional purposes, the nab-paclitaxel 
platform exploits the peculiar properties of albumin trans-
port to be conveyed directly into the tumor cells with high 
drug concentrations and therapeutic doses.12,13 Moreover, 
the nab platform eliminates the need to use toxic solvents 
thanks to the hydrophobic binding with albumin which also 
allows the infusion of significantly higher doses of paclitaxel 
compared to the doses used with standard therapy and with 
shorter infusion times (30 minutes vs 3 hours, respectively) 
without premedication.14 Nab-paclitaxel has been developed 
to improve the already known antitumor activity of con-
ventional paclitaxel in terms of greater efficacy and better 
tolerability. In several phase II and phase III studies,15,16 the 
efficacy and safety of nab-paclitaxel was evaluated in the 
treatment of patients with MBC, even in women pretreated 
with anthracyclines, both at the dose of 260 mg/m2 as a 
3-week (q3w) and 150 mg/m2 weekly regimen. These studies 
showed that nab-paclitaxel was superior to other conven-
tional taxanes in terms of overall response rate (ORR) and 
progression-free survival (PFS), with favorable toxicity and a 
favorable safety profile of nab-paclitaxel compared to pacli-
taxel. Guidelines by the National Comprehensive Cancer 
Network currently lists the taxanes solvent-based paclitaxel, 
docetaxel, and nab-paclitaxel as agents recommended for the 
treatment of recurrent and MBC.17–19 According to clinical 
studies, the main purpose of this study is to evaluate the 
safety and efficacy of Abraxane® in patients with MBC after 
first-line treatment.
study design
This retrospective study was conducted to evaluate the safety 
and efficacy of nab-paclitaxel (Abraxane®) monotherapy in 
adult patients with progressive MBC after first-line treat-
ment. Such as previous studies,20-22 OS, PFS, and ORR were 
primary endpoints, the reduction of carbohydrate antigen 
(Ca15.3), QoL, and tolerability were assessed as the second-
ary end-point.
Methods
Patients’ selection
In this retrospective study, 90 patients diagnosed with MBC 
were enrolled from September 2012 to December 2017 in 
the Medical Oncology Unit of the University of Palermo and 
ARNAS Palermo Civico Hospital. This study was approved 
by ethics committee Policlinico “P. Giaccone” Palermo. 
The study was conducted according to the Declaration of 
Helsinki; all patients provided written informed consent 
before undergoing any study specific procedures. All 
previously treated patients in the first metastatic line were 
enrolled in the study and had to satisfy the following inclu-
sion criteria: (1) histologically or cytologically confirmed 
diagnosis (MBC); (2) not pregnant, not lactating females; 
(3) performance status between 0 and 2 according to the 
Eastern Cooperative Oncology Group (ECOG); (4) all 
enrolled patients had to be progressed after a first-line 
treatment; (5) cardiac function (ventricular systolic frac-
tion EF .50%); (6) clinical and radiological evidence of 
metastatic disease with a number of lesions $1 and (7) with 
the following laboratory results: neutrophils .2.0×109/L; 
platelets .100×109/L; hemoglobin .10 g/dL; creati-
nine ,1 mg/dL, the upper limit of the standard (ULN); cre-
atinine clearance .60 mL/min if creatinine was above the 
indicated limit; bilirubin ,1×ULN; aspartate aminotransfer-
ase (AST) and alanine aminotransaminase (ALT) ,5×ULN; 
and alkaline phosphatase ,5×ULN (except in the presence 
of bone metastases). Patients with asymptomatic central 
nervous system metastases were approved, and treatment 
with surgery or radiation therapy of brain lesions should have 
been completed no more than 3 months before study entry. 
Patients who were hypersensitive to nab-paclitaxel and its 
excipients, or to other components of the formulation or with 
a diagnosis of other malignancies were excluded, except for 
basal cell carcinoma of the skin, adequately treated, patients 
with symptomatic brain metastases or patients presenting 
severe comorbidity not adequately controlled by other 
ongoing therapies (eg, liver disease, diabetes, infections, 
heart disease, etc). Other concomitant anticancer therapies 
were not admitted, and radiotherapy to extracranial sites 
or hormonal therapy should be terminated at least 1 month 
before starting nab-paclitaxel treatment.
evaluation on the response and toxicity
Evaluation of the response rate in terms of measurable dis-
ease reduction according to the response criteria for solid 
tumor response (RECIST version 1.1) was conducted at the 
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beginning of treatment cycle, then every 3 months until dis-
ease progression. The spiral computed tomography scan with 
and without contrast medium was always performed before 
the beginning of treatment cycle, and then every 3 months 
until the disease progressed, and whenever an increase of 
Ca15.3 or a presumed clinical progression was recorded. 
Total body bone scintigraphy was always performed ini-
tially before treatment and then at the discretion of the 
physician and the characteristics of the patient, every 6 or 
12 months. Total body positron emission tomography scan 
was performed at the discretion of the oncologist physician 
for any suspected progression of the disease. In the case of 
brain metastases, a magnetic resonance imaging scan was 
performed every 12 weeks. Treatment continued until clini-
cal benefit was observed or until treatment was no longer 
tolerated. Treatment-related toxicity and side effects were 
assessed at the end of each treatment cycle and reported in 
line with the Cancer Therapy Evaluation Program, Common 
Terminology Criteria for Adverse Events (CTCAE), Ver-
sion 4.0. The Ca15.3 was determined before each treatment 
cycle and subsequently, every 3 months if positive. The 
progression of Ca15.3 was considered as: (1) an increase 
of Ca15.3$25% compared to the baseline values in those 
patients who did not obtain a significant reduction ($50%) 
of the serum Ca15.3 levels during treatment; (2) an increase 
of $50% of the lowest level observed in patients who 
achieved a significant ($50%) reduction of serum Ca15.3 
levels during treatment.
Method of administration
Patients were given nab-paclitaxel (Abraxane®; Celgene 
Corporation, Summit, NJ, USA) at 260 mg/m2 intravenous 
over 30 minutes every 3 weeks without premedication 
of steroids or antihistamine or programmed support with 
granulocyte colony stimulating factor (G-CSF). Treatment 
was carried out until disease progression or the appearance 
of unacceptable toxicity. Progressive patients were assigned 
to start a new treatment. During the entire treatment period, 
adequate hydration was advised to the patient in order to 
prevent complications such as renal failure. Treatment was 
given until disease progression or the development of unac-
ceptable toxicity or patient rejection. Toxic effects of grade 
3 or 4 were managed with dose modifications or according 
to clinical practice procedures. Therapy was postponed 
for 2 weeks if the neutrophil count was ,1.5×109/L if the 
platelet count was ,100×109/L, if the hemoglobin level 
was ,8.5 g/dL, or if bilirubin and/or transaminase levels 
were .1.5×ULN. In the case of neutropenia (G2–G3), 
G-CSF was also administered, under the skin, in advance. 
If significant anemia occurred (G2–G3) blood transfusions 
were performed or in less severe cases erythropoietin vials 
under the skin, and finally for platelet therapy, steroid ther-
apy, or intravenous platelet infusion. Concomitant treatments 
that did not interfere with the evaluation of nab-paclitaxel, 
including the use of bisphosphonates or denosumab, could 
be given at the discretion of the researcher.
statistical analysis
The normality of the distribution was checked using the uni-
variate indices of skewness and kurtosis with an acceptance 
threshold equal to 1. All variables comply with normality 
indices. Descriptive statistics were useful to provide a 
sociodemographic representation and the distribution of 
all variables. The disease control rate was defined as the 
percentage of patients with an objective response and/or 
stable disease lasting .6 months. PFS and OS were calcu-
lated from the date of the initiation of treatment until the 
date of the disease progression, or death from any cause for 
PFS and until the date of the last follow-up, death, or the 
final follow-up. The date cutoff was December 2017. PFS 
and OS curves were estimated by using the Kaplan–Meier 
method. Kaplan–Meier analysis was used to generate sur-
vivals curves and estimate median survival with 95% CIs. 
The Bravais–Pearson index was used to evaluate the rela-
tionship between Ca15.3, OS, and QoL. Statistical analysis 
was performed using SPSS version 22.0 (IBM Corporation, 
Armonk, NY, USA).
Results
The demographic and clinical-pathological characteristics 
of the 90 patients with MBC are reported in Table 1. At the 
time of diagnosis, patients were aged between 36 and 83 with 
a mean age of 59 years, all of them white and most of the 
patients were post-menopause; 52 patients were ECOG 0, 28 
ECOG I and 10 ECOG II, 58 patients were HER2 negative 
and 32 HER2 positive, 56 positive hormone receptors and 
34 negative receptors, 39 patients were bone metastases, 
25 hepatic metastases, 38 pulmonary metastases, 68 lymph 
node metastases. Eight patients had a triple-negative MBC. 
Previous anthracyclines were administered to 85.8% of 
the patients and 80% of them had also received previous 
hormonal therapy. Our analysis shows that the treatment 
was well tolerated with a good ORR of 22%, with an OS 
median of 10.4 months and, median PFS of 6.8 months. 
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The response rate of Ca15.3–8 weeks after the end of 
treatment was .50% to correlate with improved survival. 
Treatment with Abraxane® was well tolerated and resulted in 
a good level of disease control (RC+PR+DS .50%) and the 
median duration of the response was 6 months. After a mean 
follow-up duration of 9.2 months (range: 5.2–15.2 months), 
1% of patients had a complete response (RC) the 19% had 
a PR, 34% had a disease stabilization (DS), 38% showed 
disease progression (PD), and 8% unable to determine. The 
patients with an objective response and stable disease show 
the clinical benefit rate. The ORR were slightly higher in 
HER2-negative (22%), ER and PR positive 20%–22% ER 
and PR negative 18%–20% the HER2 positive (20%) reduced 
the clinical efficacy induced by nab-paclitaxel.
Os and PFs analysis
Among the 90 patients enrolled for this study, the interim 
survival analysis (last follow-up in December 2017) showed a 
value of 10.4 months (95% CI: 8.1–14.6 months) (Figure 1). 
Median PFS was 6.8 months (95% CI: 5.9–11.6 months) 
(Figure 2). This variable is associated positively with the 
QoL, in fact, by means of the Bravais–Pearson index, a good 
correlation between these two variables has been demon-
strated with an r (95% CI) value of 0.58 and 0.59 (0.28–0.86), 
P=0.002 (Table 2).
Table 1 Demographic and clinical characteristics (n=90)
Characteristics Patients
N=90
Mean age (range) 59 (36–83)
Menopausal status (%)
Postmenopausal 61 (68)
Premenopausal 29 (32)
Previous treatment
her2+
anthracycline, cyclophosphamide and trastuzumab
her2-
anthracycline and cyclophosphamide
Triple negative
Taxolo and avastin
ECOG performance status (%)
0 52 (58)
1 28 (31)
2 10 (11)
Median Ca 15.3 
,35 ng/ml cutoff (range) 190 (180–300)
Metastatic site (%)
liver 25 (28)
lung 38 (42)
Bone 39 (43) 
lymph nodes 68 (75.5)
Abbreviation: ecOg, eastern cooperative Oncology group.
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Figure 1 Kaplan–Meier plot of median Os (interim analysis) (n=90).
Abbreviations: mOs, median overall survival; Os, overall survival.
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Figure 2 Kaplan–Meier plot of Median PFs (interim analysis) (n=90).
Abbreviations: mPFs, median progression-free survival; PFs, progression-free 
survival.
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ca15.3 reduction
The analysis of Ca15.3 values  made it possible to observe that 
after treatment with Abraxane®, .50% of patients reported 
a reduction in initial values and we showed that this reduc-
tion was linked to an increase in OS. Therefore, the Ca15.3 
response may be an important predictor of OS augmentation 
with a positive correlation obtained between the Ca15.3 
response with OS β=0.365, (P,0.01).
Tolerability
No patient died due to treatment with nab-paclitaxel. Tol-
erability was assessed based on common terminological 
criteria for adverse events at the National Cancer Institute 
(version 4.0). Overall, nab-paclitaxel therapy was well 
tolerated, the dose reductions, and dose delays were infre-
quent (3%–5%). All 90 patients in the ITT population were 
included in the safety analysis. No severe (grade 3 or 4) 
treatment-related hypersensitivity reactions occurred in 
any of the patients in the group despite the absence of pre-
medication. Treatment-related grade 3 sensory neuropathy 
occurred more frequently, but these episodes improved 
with interruption of treatment. No episodes of motor neu-
ropathy or grade 4 sensory neuropathy were reported. The 
incidence of treatment-related grade 4 neutropenia (based 
on the central laboratory test values) was 9% which required 
the use of G-CSF also as prophylaxis of 8% a grade G2–G3 
platelet which required the use of corticosteroids and 15% 
had anemia (G2–G3) that required the administration of 
erythropoietin toxicity was assessed through clinical evalu-
ation, total blood cells and complete serum chemistry and 
were classified according to national criteria of common 
toxicity. Events associated with the treatment of toxicity and 
side effects are described respectively in Table 3. No patient 
discontinued treatment due to severe side effects.
Qol 
QoL was measured using the questionnaire of the European 
Organization for the Research and Treatment of Quality of 
Life C30 (EORTC-QoL-C30) Version 3.023 and was analyzed 
as a change from baseline at each cycle. With a score of 45 
(0–100) and a global health status/QoL scales. The QoL 
showed an improvement in the treatment. Scores on the 
functional scales of the EORTC QLQ-C30 ranged indicat-
ing that the patients’ QoL was sufficient overall (Table 4). 
An improvement in QoL was also identified with a reduction 
in pain symptoms.
Discussion
Breast cancer is the most common cancer in the female 
population and is the leading cause of cancer death in women 
Table 2 Pearson’s correlation among ca15.3, Os, and Qol 
(n=90)
Comparisons Ca 15.3 OS QoL P-value
ca 15.3 1 -0.59* -0.58* 0.002
Os -0.59* 1 0.59* 0.002
Qol -0.58* 0.59* 1 0.005
Note: *P,0.01.
Abbreviations: ca15.3, carbohydrate antigen 15.3; Os, overall survival; Qol, 
quality of life.
Table 3 adverse events grade with common Terminology 
criteria for adverse events, version 4.0 (n=90)
Adverse event Patients (%)
Hematological
grade 2 anemia  36
grade 3 anemia  64
grade 2 neutropenia  27
grade 3 neutropenia  72
Febrile neutropenia  37
grade 1–2 thrombocytopenia  6
Nonhematological
grade 3 asthenia  30
grade 2–3 peripheral neuropathy  45
grade 3 stomatitis  10
alopecia  90
grade 2 skin reactions  3
grade 2–3 diarrhea  7
Table 4 Mean and sD of the eOrTc-QlQ-c30 (n=90)
Quality of life Mean (SD)
Physical functioning 78.3 (17.5)
role functioning 69.9 (30.6)
emotional functioning 83.3 (24.4)
cognitive functioning 81.6 (28.5)
social functioning 79.4 (27.9)
global health/Qol 45.3 (21.6)
insomnia 26.4 (28.8)
Fatigue 62.3 (25.3)
Pain 18.8 (27.4)
Dyspnea 18.4 (36.1)
constipation 26.5 (16.9)
appetite loss 28.7 (29.2)
Diarrhea 52.4 (19.5)
nausea, vomiting 39.3 (21.4)
Financial difficulties 47.7 (29.7)
Abbreviations: eOrTc-QlQ-c30, european Organization for the research and 
Treatment of Quality of life c30; Qol, quality of life.
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in more developed countries, despite progress in screening 
and treatment. In Italy about 7% of women have an MBC 
at the first diagnosis, and the risk of relapse at ten years 
is about 70% in women with positive histological lymph 
nodes.24 The primary goals of chemotherapy treatment in 
MBC patients are to prolong survival and improve QoL and 
control symptoms. This study aims to evaluate the efficacy of 
nab-paclitaxel (Abraxane®) as monotherapy in Italian patients 
with progressing MBC after a first-line chemotherapy regi-
men.25 Taxanes have been widely proven to be among the 
most active cytotoxic drugs for the treatment of breast cancer 
and, since their advent, have provided a new chemotherapy 
option in the treatment of patients with MBC.26 The new 
solvent-free formulation of paclitaxel, nab-paclitaxel, has 
shown good safety and a good efficacy profile.27,28 Our results, 
even if with a limited number of patients, are in agreement 
with the clinical evidence reported in the literature and result 
in a recent and updated analysis of the survival data of the 
Phase III trial of nanoparticle albumin-bound paclitaxel 
compared with polyethylated castor oil-based paclitaxel in 
women with breast cancer by which it was confirmed that the 
treatment with nab-paclitaxel determines an improvement in 
the OS rate, and PFS associated with a reduction of the values 
of Ca15.3. In particular, the reduction of Ca15.3 was .54%, 
and we have also shown that this reduction was linked to an 
increase in the OS. Therefore, the Ca15.3 response can be 
an important predictor of OS augmentation. Furthermore, 
our analysis shows that this treatment was well tolerated and 
associated with a good objective response rate, only 9% of 
patients developed severe neutropenia (grade 3 CTCAE). 
This result is in agreement with the published data show-
ing a greater risk of mild–moderate side effects associated 
with nab-paclitaxel treatment. In our study, we also found 
a significant impact of nab-paclitaxel on pain reduction and 
this was linked to better survival and improvement of QoL.29 
We realize, however, that despite our results being in line 
with those reported in the literature, there are limits that 
must be taken into consideration, related for example, to the 
evaluation of the response and to the small size of the sample.
Conclusion
Nab-paclitaxel monotherapy is effective, well tolerated, 
safe, and the toxicity associated with treatment is accept-
able. Response rates, safety, and improvement of the QoL 
are satisfactory. Based on these results, we can conclude 
that nab-paclitaxel treatment every 3 weeks is a valuable 
regimen for the progressive form of MBC. Furthermore, nab-
paclitaxel shows several advantages over existing taxanes, 
facilitating drug administration and improving patient accep-
tance, particularly due to the absence of premedication with 
corticosteroids or prolonged infusions or special intravenous 
infusion sets. The use of nab-paclitaxel monotherapy in MBC 
is supported by clear efficacy data, and post-approval clinical 
studies have confirmed its role in the treatment of MBC. In 
conclusion, this innovative formulation of albumin-bound 
paclitaxel has a significant antitumor activity and a manage-
able safety profile in patients pretreated after at least one 
line of chemotherapy; this cytotoxic drug was shown to be 
aggressive in breast cancer, such as triple-negative tumors. 
Our results, even with a limited number of patients, are in 
agreement with the clinical evidence reported in the literature.
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